Type 1 narcolepsy is caused by a loss of hypocretin (orexin) signaling in the brain. Genetic data suggests the disorder is caused by an autoimmune attack on hypocretin producing neurons in hypothalamus. This hypothesis has however not yet been confirmed by consistent findings of autoreactive antibodies or T-cells in patient samples. One explanation for these negative results may be that the autoimmune process is no longer active when patients present to the clinic. With increasing awareness in recent years, more and more patients have been diagnosed closer and closer to disease onset. In this study, we tested whether an active immune process in the brain could be detected in these patients, as reflected by increased cytokine levels in the cerebrospinal fluid (CSF). Using multiplex analysis, we measured the levels of 51 cytokines and chemokines in the CSF of 40 type 1 narcolepsy patients having varying disease duration. For comparison, we used samples from 9 healthy controls and 9 patients with other central hypersomnia. Cytokine levels did not differ significantly between controls and patients, even in 5 patients with disease onset less than a month prior to CSF sampling.
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Introduction
The sleep disorder type 1 narcolepsy is caused by a loss of hypocretin (hcrt, also known as orexin) in the brain (ISCD-3, 2014) . In addition most of the patients also suffer from the pathognomonic symptom cataplexy (muscle atonia triggered by emotions).
Autoimmunity due to environmental triggers is considered the most likely pathogenesis (Partinen et al., 2014) , an hypothesis strengthened by the report of increased numbers of cases after H1N1-vaccinations or infections (Dauvilliers et al., 2010; Han et al., 2011; Partinen et al., 2012) . Despite this, experimental proof of autoimmunity in narcolepsy is still missing. One reason for this lack of evidence may be that the autoimmune process is no longer active when patients present to the clinic. Several observations suggest that this could indeed be the case. First, type 1 narcolepsy patients typically have low or even undetectable levels of hypocretin-1 (hcrt-1) neuropeptide in cerebrospinal fluid (CSF) suggesting that the autoimmune destruction of the neurons is nearly complete already at the time of diagnosis (Nishino et al., 2000) . Second, cases with intermediate levels are rarely seen (Andlauer et al., 2012; Bourgin et al., 2008; Knudsen et al., 2010) . Finally, observations of onset a few weeks to months following H1N1 Pandemrix vaccinations, suggest that the disease process can occur in weeks to a few months (Knudsen et al., 2012; Partinen et al., 2012) . In the case of immune responses towards viral infections, the virus is typically cleared within few weeks (Carrat et al., 2008; Ennis et al., 1981) , thus immune factors resulting from the autoimmune process may decrease rapidly.
In the past, diagnostic delay for narcolepsy was very long, over 10 years in most cases (Thorpy and Krieger, 2014 
